CCAR2 and pancreatic neoplasm: One could envision a combination therapy of a SIRT1 inhibitor and one of these drugs that target the metabolism of the pancreatic tumor or one could potentially use low CCAR2 expression, likely corresponding to high SIRT1 activity, as a biomarker to select a population of early stage PDAC patients for therapy with drugs that target the glycolytic metabolism.